197 related articles for article (PubMed ID: 12925523)
1. The relationship between virologic and immunologic responses in AIDS clinical research using mixed-effects varying-coefficient models with measurement error.
Liang H; Wu H; Carroll RJ
Biostatistics; 2003 Apr; 4(2):297-312. PubMed ID: 12925523
[TBL] [Abstract][Full Text] [Related]
2. Analysis of relation between virologic responses and immunologic responses, patient's factors in AIDS clinical trials using a semiparametric mixed-effects model.
Liang H; Zou G
Biom J; 2007 Jun; 49(3):406-15. PubMed ID: 17623345
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inference for longitudinal data with detection limits and covariates measured with errors, with application to AIDS studies.
Wu L
Stat Med; 2004 Jun; 23(11):1715-31. PubMed ID: 15160404
[TBL] [Abstract][Full Text] [Related]
4. CPCRA to use viral load as marker for treatment. Community Programs for Clinical Research on AIDS.
AIDS Alert; 1995 Aug; 10(8):105-7. PubMed ID: 11362678
[TBL] [Abstract][Full Text] [Related]
5. Modeling the short-, middle- and long-term viral load responses for comparing estimated dynamic parameters.
Huang Y
Biom J; 2007 Jun; 49(3):429-40. PubMed ID: 17623347
[TBL] [Abstract][Full Text] [Related]
6. The study of long-term HIV dynamics using semi-parametric non-linear mixed-effects models.
Wu H; Zhang JT
Stat Med; 2002 Dec; 21(23):3655-75. PubMed ID: 12436462
[TBL] [Abstract][Full Text] [Related]
7. Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies.
Huang Y; Dagne G
Stat Med; 2010 Oct; 29(23):2384-98. PubMed ID: 20603815
[TBL] [Abstract][Full Text] [Related]
8. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
[TBL] [Abstract][Full Text] [Related]
9. Evaluating surrogate markers of clinical outcome when measured with error.
Dafni UG; Tsiatis AA
Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
[TBL] [Abstract][Full Text] [Related]
10. Immunologic and virologic markers determining progression to AIDS.
Schellekens PT; Koot M; Roos MT; Tersmette M; Miedema F
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S62-6. PubMed ID: 7552515
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection.
Andrieu JM; Lu W
BMC Med; 2004 May; 2():17. PubMed ID: 15128452
[TBL] [Abstract][Full Text] [Related]
12. Multiple augmentation for interval-censored data with measurement error.
Song X; Ma S
Stat Med; 2008 Jul; 27(16):3178-90. PubMed ID: 18040984
[TBL] [Abstract][Full Text] [Related]
13. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
14. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
15. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
16. Modelling progression of CD4-lymphocyte count and its relationship to survival time.
De Gruttola V; Tu XM
Biometrics; 1994 Dec; 50(4):1003-14. PubMed ID: 7786983
[TBL] [Abstract][Full Text] [Related]
17. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.
Blattner WA; Oursler KA; Cleghorn F; Charurat M; Sill A; Bartholomew C; Jack N; O'Brien T; Edwards J; Tomaras G; Weinhold K; Greenberg M
J Infect Dis; 2004 May; 189(10):1793-801. PubMed ID: 15122515
[TBL] [Abstract][Full Text] [Related]
18. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
19. A flexible B-spline model for multiple longitudinal biomarkers and survival.
Brown ER; Ibrahim JG; DeGruttola V
Biometrics; 2005 Mar; 61(1):64-73. PubMed ID: 15737079
[TBL] [Abstract][Full Text] [Related]
20. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
